Fundraising FoxInsamo
Chippendale, AU · Founded 2022 · Delaware corporation · 7 known investors
Find your way into Insamo
Sign up to see every warm intro you have to Insamo
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Insamo team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Insamo develops an automated platform for drug discovery that designs, synthesizes, and tests cyclic peptides at scale using machine learning and proprietary experimental data. The company targets the development of treatments for challenging diseases through membrane-permeable and orally available compounds.
Founders & leadership
Board
Investors · 7
How we know: Civilization Ventures Management, Llc's portfolio page · the VCSheet dataset · Not right? Tell us
How we know: MRL Ventures Fund's portfolio page · Not right? Tell us
How we know: Playground Global's portfolio page · a partner's Signal profile · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: a partner's Signal profile · the VCSheet dataset · Not right? Tell us
How we know: the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$11.8M disclosed across 2 rounds · 2023
▶$2.3MraisedDec 2023 · 2 investors · BiotechnologyRule 506(b)
- COREY GOODMANDirector
- TOBY PASSIOURAExecutive Officer, Director
- MATT HERSHENSONDirector
- GLEN MCINTYREExecutive Officer, Director
- TIMOTHY CRAVENExecutive Officer, Director
- Offering amount
- $2.3M
- Amount sold
- $2.3M
- First sale
- Dec 2023
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
▶$9.5MraisedMar 2023 · 4 investors · BiotechnologyRule 506(b)
- COREY GOODMANDirector
- TIMOTHY CRAVENExecutive Officer, Director
- MATT HERSHENSONDirector
- TOBY PASSIOURAExecutive Officer, Director
- GLEN MCINTYREExecutive Officer, Director
- Offering amount
- $10M
- Amount sold
- $9.5M
- First sale
- Mar 2023
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 4
Companies working in the same space as Insamo.
Frequently asked questions
- What does Insamo do?
- Insamo develops an automated platform for drug discovery that designs, synthesizes, and tests cyclic peptides at scale using machine learning and proprietary experimental data. The company targets the development of treatments for challenging diseases through membrane-permeable and orally available compounds.
- Who are Insamo's investors?
- Insamo's investors include BEVC, Civilization Ventures Management, Llc, MRL Ventures Fund, Playground Global, venBio Partners, Axial VC, venBio Global Strategic.
- How much funding has Insamo raised?
- Insamo has disclosed $11.8M raised across 2 rounds.
- Where is Insamo headquartered?
- Insamo is headquartered in Chippendale, AU.